2017 Fiscal Year Final Research Report
Research and development of the tumor target anticancer agent using carbohydrate mimic peptide IF7
| Project/Area Number |
15H04982
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
村上 浩雄 浜松医科大学, 医学部附属病院, 助教 (10432212)
柴田 俊章 浜松医科大学, 医学部, 助教 (50529568)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | DDS型抗腫瘍薬 |
|---|
| Outline of Final Research Achievements |
IF7 bound to annexin 1 (Anxa1), which the endothelial surface receptor. Because Anxa1 is a highly specific tumor vasculature surface marker, we confirmed that the IF7 peptide could target anticancer drugs to the tumor vasculature. Then, we synthesized highly-pure new anticancer drug IF7-TXL which conjugate paclitaxel (TXL) with IF7 and investigated the antitumor effect using a cancer bearing mouse. In consideration of a future of IF7, we synthesized D-type IF7 and developed the antineoplastic agent of the hybrid peptide type based on new efficacy. We showed excellent antitumor effect in a highly-detailed pharmacological test.
|
| Free Research Field |
産婦人科学
|
